Ebola fears driv­ing stock win­ners

Financial Mirror (Cyprus) - - FRONT PAGE -

Fears of Ebola have plagued the United States since late Septem­ber, and some biotech com­pa­nies have cap­i­talised on this fear. Th­ese fears and some hopes of po­ten­tial con­tracts or in­creased or­ders have been ac­counted for and prices have risen as a re­sult in some of the key Ebola stocks.

In Mon­day’s pre­mar­ket trad­ing, iBio Inc. (NYSEMKT: IBIO) has been the big­gest win­ner, up more than 80% to $2.66 from Fri­day’s close of $1.47. This is on the heels of Fri­day’s rally of more than 80% from its Thurs­day close of $0.80. The company is re­ported to be a player in a gov­ern­ment ef­fort to ramp up pro­duc­tion of an Ebo­lare­lated drug, ZMapp. iBio uses the iBioLaunch plat­form, which is a pro­pri­etary gene ex­pres­sion tech­nol­ogy ca­pa­ble of pro­duc­ing high lev­els of tar­get pro­teins in plants. Ul­ti­mately th­ese pro­teins are used to cre­ate vac­cines and can be pro­duced quickly and ef­fi­ciently. By part­ner­ing with Mapp Bio­phar­ma­ceu­ti­cals, the pro­ducer of ZMapp, they can bring its Ebola treat­ment to mar­ket quicker than pre­vi­ously ex­pected. iBio’s shares have a con­sen­sus an­a­lyst price tar­get of $3.00 and a 52-week trad­ing range of $0.24 to $1.57.

Lake­land In­dus­tries Inc. (NAS­DAQ: LAKE) has been another ben­e­fi­ciary of the “Ebola out­break.” This haz­mat­suit maker has seen its stock shoot up roughly 216% to a high on Fri­day of $21.94 from its close on Septem­ber 30 of $6.95. In Mon­day’s pre­mar­ket, the stock was up about 16% to $22.80 from the pre­vi­ous close of $19.63. Shares of Lake­land have a con­sen­sus an­a­lyst price tar­get of $7.35 and a 52-week trad­ing range of $4.75 to $21.94.

Al­lied Health­care Prod­ucts Inc. (NAS­DAQ: AHPI) saw its shares take a large uptick on Fri­day, gain­ing 78% to reach $3.30 from the pre­vi­ous close of $1.85. This rally con­tin­ued into the pre­mar­ket Mon­day as shares were up another 10% to $3.65. Al­lied Health­care is a man­u­fac­turer of res­pi­ra­tory ther­apy and emer­gency med­i­cal sup­plies. It would ap­pear that the company has fi­nally re­ceived recog­ni­tion for what role it can play in this Ebola saga with its emer­gency and res­pi­ra­tory equip­ment. Its stock has a con­sen­sus an­a­lyst price tar­get of $4.51 and a 52-week trad­ing range of $1.60 to $3.90.

Tek­mira Phar­ma­ceu­ti­cals Corp. (NAS­DAQ: TKMR) shares were cor­rect­ing in Mon­day’s pre­mar­ket after tak­ing a hit on Fri­day. Shares were down roughly 4% to close at $22.80 on Fri­day, while they gained almost 6% in the pre­mar­ket to $24.14 on Mon­day. The company’s shares have a con­sen­sus an­a­lyst price tar­get of $27.54 and a 52week trad­ing range of $7.17 to $31.48.

Sarepta Ther­a­peu­tics Inc. (NAS­DAQ: SRPT) was up only about 1.8% at $19.19 shortly after the open.

Newspapers in English

Newspapers from Cyprus

© PressReader. All rights reserved.